highperformr logo

Cabaletta Bio's Overview

Total employees174
HeadquartersPhiladelphia
Founded2017

Cabaletta Bio (NASDAQ: CABA) is a clinical-stage biotechnology company dedicated to discovering and developing T cell therapies for B cell-mediated autoimmune diseases. Their proprietary Chimeric AutoAntibody Receptor (CAAR) T cell technology aims to selectively eliminate B cells that produce disease-causing autoantibodies. Their lead product candidate, CABA-201, a 4-1BB-containing fully human CD19-CAR T therapy, is being evaluated for various autoimmune conditions including systemic lupus erythematosus, myositis, generalized myasthenia gravis, and systemic sclerosis.

Where is Cabaletta Bio's Headquarters?

HQ Function

Serves as the primary center for Cabaletta Bio's research and development, clinical operations, strategic planning, and corporate administration.

Notable Features:

The headquarters is located in a modern office building in Philadelphia's University City district, providing advanced laboratory and office facilities designed to support scientific research and collaboration.

Work Culture:

Cabaletta Bio fosters a science-driven, innovative, and collaborative work environment. The culture emphasizes patient-centricity, teamwork, and a commitment to scientific excellence in developing transformative therapies.

HQ Significance:

Its Philadelphia location provides strategic access to a rich ecosystem of academic institutions, research organizations, talent, and potential collaborators in the biotechnology and pharmaceutical sectors.

Values Reflected in HQ: The headquarters' focus on state-of-the-art facilities and its location in a leading biotech hub reflect Cabaletta Bio's commitment to innovation, scientific rigor, and addressing unmet medical needs in autoimmune diseases.

Location:

Cabaletta Bio is primarily based in the United States, with its headquarters in Philadelphia, PA. While its core operations are U.S.-centric, its clinical trials for product candidates like CABA-201 may involve multiple sites nationally and potentially internationally, collaborating with research institutions and clinical centers to advance its therapeutic programs for patients with autoimmune diseases.

Street Address:

2929 Arch Street, Suite 600

City:

Philadelphia

State/Province:

PA

Country:

USA

Cabaletta Bio's Global Presence

Buying Intent Signals for Cabaletta Bio

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Cabaletta Bio

As of April 2025, Cabaletta Bio' leadership includes:

Steven Nichtberger, M.D. - Co-founder, President, Chief Executive Officer and Chairman
Gwendolyn Binder, Ph.D. - President, Science and Technology
Arun Das, M.D. - Chief Business Officer
Michael Gerard - Chief Financial Officer
Gavin Rochford - Chief Operating Officer
David J. Chang, M.D., M.P.H. - Chief Medical Officer
Heather Attra - Chief People Officer

Investors of Cabaletta Bio

Cabaletta Bio has been backed by several prominent investors over the years, including:

5AM Ventures
Adage Capital Management L.P.
Deerfield Management
RA Capital Management
Redmile Group
Boxer Capital of Tavistock Group

Executive New Hires/Exits in the Last 12 Months

Hire3
Exits2

Over the past 12 months, Cabaletta Bio has strengthened its executive team with key appointments, including a new Chief Financial Officer, Chief People Officer, and Chief Medical Officer, alongside a significant promotion for its head of R&D. These changes support the company's growth and advancement of its clinical pipeline.

Departures

Anup Marda, Anup Marda departed as CFO.
Samik Basu, M.D., Samik Basu, M.D., departed as Chief Medical Officer.

New Appointments:

Michael Gerard, Michael Gerard appointed as Chief Financial Officer.
Heather Attra, Heather Attra appointed as Chief People Officer.
David J. Chang, M.D., M.P.H., David J. Chang, M.D., M.P.H., appointed as Chief Medical Officer.
Gwendolyn Binder, Ph.D., Gwendolyn Binder, Ph.D., promoted to President, Science and Technology.

Technology (Tech Stack) used by Cabaletta Bio

Discover the tools Cabaletta Bio uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Cabaletta Bio Email Formats and Examples

Cabaletta Bio commonly uses the email format where the first initial is followed by the last name, such as 'jdoe@cabalettabio.com'. This is a prevalent pattern among employees for official communications.

[first_initial][last]@cabalettabio.com

Format

snichtberger@cabalettabio.com

Example

85%

Success rate

News and media

GlobeNewswireMay 9, 2024

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Cabaletta Bio announced its Q1 2024 financial results, provided updates on its CABA-201 clinical program for lupus and myositis, noted IND clearance for CABA-201 in generalized myasthenia gravis, and announced the promotion of Gwendolyn Binder, Ph.D., to President, Science and Technology....more

GlobeNewswireMarch 11, 2024

Cabaletta Bio Appoints David J. Chang, M.D., M.P.H. as Chief Medical Officer

David J. Chang, M.D., M.P.H. was appointed as Cabaletta Bio's new Chief Medical Officer to lead the company's clinical development and medical affairs strategy....more

GlobeNewswireFebruary 15, 2024

Cabaletta Bio Announces U.S. FDA Clearance of IND Application for CABA-201 for the Treatment of Systemic Sclerosis

The U.S. Food and Drug Administration (FDA) cleared Cabaletta Bio's Investigational New Drug (IND) application for CABA-201, allowing the initiation of a Phase 1/2 clinical trial for patients with systemic sclerosis....more

GlobeNewswireDecember 4, 2023

Cabaletta Bio Appoints Heather Attra as Chief People Officer

Heather Attra joined Cabaletta Bio as Chief People Officer, bringing extensive experience in human resources and talent management within the life sciences industry to lead the company's people strategy....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Cabaletta Bio, are just a search away.